The global Treatment Resistant Depression Market is estimated to be valued at US$ 1220.12 Mn or in 2023 and is expected to exhibit a CAGR of 3.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Treatment resistant depression refers to depression that does not improve after several antidepressant treatments. The market mainly consists of drugs used to treat patients with depression who have not responded to standard antidepressant therapies. These drugs provide alternative treatment options and improved patient outcomes.
Market key trends:
Growing research on combination therapies for treatment resistant depression is a key trend driving market growth. Combination therapies have emerged as a promising treatment approach for such cases and involve use of antidepressants along with other drugs like antipsychotics, mood stabilizers or anti-anxiety drugs. Recent clinical trials have demonstrated effectiveness of combination of different classes of antidepressants for patients not responding to single drug therapies. This has boosted research on new combination therapies and expanded treatment choices available to patients.
Incorporating personalized medicine approach is another trend, as determining the most effective therapy depends on individual patient factors like history of medications tried, side effects experienced and genetic differences influencing drug metabolism. This allows for customized treatment plans targeting specific molecular pathways and profiles.
SWOT Analysis
Strength: Treatment Resistant Depression (TRD) market has a well-established diagnosis and treatment guidelines. The market has presence of several drugs and treatment options for patients not responding to first line therapies.
Weakness: High costs associated with newer therapies such as gene therapies and digital therapeutics. Lack of biomarkers for early identification of patients at risk of becoming treatment resistance.
Opportunity: Emerging digital therapeutics and neuromodulation devices offer non-pharmacological treatment options. Growing research on identifying biomarkers and predictors of treatment response.
Threats: Presence of alternative treatment approaches such as psychotherapy, yoga, and meditation. Patent expiry of blockbuster drugs resulting in cheaper generics competition.
Key Takeaways
The Global Treatment Resistant Depression Market Size is expected to witness high growth, exhibiting CAGR of 3.4% over the forecast period, due to increasing prevalence of mental health disorders and lack of effective treatment options for TRD patients.
Regional analysis
North America dominated the global market in 2023 and is expected to maintain its lead over the forecast period owing to high mental healthcare expenditure and availability of advanced therapies. Asia Pacific is anticipated to exhibit the fastest growth attributable to rising patient pool, gaining awareness and improving access to treatment.
Key players
Key players operating in the Treatment Resistant Depression market are AbbVie Inc., Lupin, Eli Lilly and Company, GlaxoSmithKline Plc., Pfizer Inc., Bausch Health Companies Inc., Sanofi, Mallinckrodt, Johnson & Johnson, Merck & Co., Inc., Viatris Inc., Otsuka Holdings Co., Ltd., H. Lundbeck A/S, AstraZeneca, and Aurobindo Pharma Ltd.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
